PPARA and metabolic dysfunction-associated steatotic liver disease: The activation of PPARα seems to be a promising target in the treatment of NAFLD because PPARα is also a key regulator of the genes involved in fatty acid oxidation [33–36] and anti-inflammatory effects [37, 38].